The initiation of coverage by Scotiabank with a Sector Perform rating suggests that the bank sees Kura Oncology's stock performing in line with the sector average. The price target of $10.5 indicates where the bank believes the stock price will move in the short term. This news is highly relevant to Kura Oncology and moderately important for investors. The score is neutral as the rating suggests average performance.